proteus infections

Summary

Summary: Infections with bacteria of the genus PROTEUS.

Top Publications

  1. ncbi Clinical epidemiology of ciprofloxacin-resistant Proteus mirabilis isolated from urine samples of hospitalised patients
    R Saito
    Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan
    Clin Microbiol Infect 13:1204-6. 2007
  2. pmc Classification, identification, and clinical significance of Proteus, Providencia, and Morganella
    C M O'Hara
    Hospital Infections Program, Division of Bacterial and Mycotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Clin Microbiol Rev 13:534-46. 2000
  3. pmc Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases
    Andrea Endimiani
    Laboratorio di Microbiologia, Ospedale di Circolo e Università dell Insubria, Viale Borri 57, 21100 Varese, Italy
    Antimicrob Agents Chemother 49:2598-605. 2005
  4. ncbi A simple phenotypic method for differentiation between acquired and chromosomal AmpC beta-lactamases in Escherichia coli
    Beatriz Mirelis
    Servicio de Microbiologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Espana
    Enferm Infecc Microbiol Clin 24:370-2. 2006
  5. pmc Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis
    S M Jacobsen
    Department of Biomedical Sciences, Dental School, University of Maryland Baltimore, Room 9209, 650 W Baltimore Street, Baltimore, MD 21201, USA
    Clin Microbiol Rev 21:26-59. 2008
  6. ncbi Bacteraemia due to tribe Proteeae: a review of 132 cases during a decade (1991-2000)
    Baek Nam Kim
    Division of Infectious Diseases, Keimyung University Dongsan Medical Center, Daegu, Korea
    Scand J Infect Dis 35:98-103. 2003
  7. pmc The Dienes phenomenon: competition and territoriality in Swarming Proteus mirabilis
    A E Budding
    VU Medical Centre, Department of Medical Microbiology and Infection Prevention, Amsterdam, The Netherlands
    J Bacteriol 191:3892-900. 2009
  8. ncbi [Proteus bacilli: features and virulence factors]
    Antoni Rozalski
    Zakład Immunobiologii Bakterii, Instytut Mikrobiologii i Immunologii Uniwersytetu Łódzkiego, Poland
    Postepy Hig Med Dosw (Online) 61:204-19. 2007
  9. ncbi [Enzymatic resistance to beta lactam antibiotics within the genus Proteus and evaluation of Proteus mirabilis phenotypes and genotypes for resistance to third- and fourth-generation cephalosporins]
    Cynthia Rodriguez
    Cátedra de Análisis Clínicos I, Laboratorio de Bacteriologia, Hospital de Clinicas, Universidad de Buenos Aires, Argentina
    Enferm Infecc Microbiol Clin 23:122-6. 2005
  10. ncbi [Proteus penneri]
    Rafael Canton
    Servicio de Microbiologia, Hospital Universitario Ramon y Cajal, Madrid, Espana
    Enferm Infecc Microbiol Clin 24:8-13. 2006

Research Grants

  1. Molecular Pathogenesis of E. Coli UTI
    HARRY MOBLEY; Fiscal Year: 2006
  2. Reciprocal Control of Motility and Adherence in UTI
    HARRY MOBLEY; Fiscal Year: 2007
  3. UREASE AND GENE EXPRESSION OF HELICOBACTER PYLORI
    HARRY MOBLEY; Fiscal Year: 2007
  4. Molecular Pathogenesis of E. Coli UTI
    HARRY MOBLEY; Fiscal Year: 2009
  5. Development of a Urea Biosensor Using the UreR Protein
    HARRY MOBLEY; Fiscal Year: 2004
  6. UREASE AND GENE EXPRESSION IN CAMPYLOBACTER PYLORI
    HARRY MOBLEY; Fiscal Year: 1991
  7. MOLECULAR PATHOGENESIS OF E COLI UTI
    HARRY MOBLEY; Fiscal Year: 2001
  8. UREASE AND GENE EXPRESSION OF HELICOBACTER PYLORI
    HARRY MOBLEY; Fiscal Year: 2003

Detail Information

Publications155 found, 100 shown here

  1. ncbi Clinical epidemiology of ciprofloxacin-resistant Proteus mirabilis isolated from urine samples of hospitalised patients
    R Saito
    Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan
    Clin Microbiol Infect 13:1204-6. 2007
    ..The majority of ciprofloxacin-resistant P. mirabilis isolates were multiresistant, and ciprofloxacin resistance was associated significantly with previous use of fluoroquinolones and production of extended-spectrum beta-lactamases...
  2. pmc Classification, identification, and clinical significance of Proteus, Providencia, and Morganella
    C M O'Hara
    Hospital Infections Program, Division of Bacterial and Mycotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Clin Microbiol Rev 13:534-46. 2000
    ..Many of these organisms are easily controlled, but the advent of newer and more powerful antimicrobial agents has led to some problems of which laboratorians need to be aware...
  3. pmc Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases
    Andrea Endimiani
    Laboratorio di Microbiologia, Ospedale di Circolo e Università dell Insubria, Viale Borri 57, 21100 Varese, Italy
    Antimicrob Agents Chemother 49:2598-605. 2005
    ..mirabilis isolates. Thus, recognition of ESBL-positive strains appears to be critical for the clinical management of patients with systemic P. mirabilis infections...
  4. ncbi A simple phenotypic method for differentiation between acquired and chromosomal AmpC beta-lactamases in Escherichia coli
    Beatriz Mirelis
    Servicio de Microbiologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Espana
    Enferm Infecc Microbiol Clin 24:370-2. 2006
    ..The purpose of this study was to assess screening methods for the detection of these enzymes in clinical isolates of Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis...
  5. pmc Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis
    S M Jacobsen
    Department of Biomedical Sciences, Dental School, University of Maryland Baltimore, Room 9209, 650 W Baltimore Street, Baltimore, MD 21201, USA
    Clin Microbiol Rev 21:26-59. 2008
    ..Research focusing on the pathogenesis of CAUTIs will lead to a better understanding of the disease process and will subsequently lead to the development of new diagnosis, prevention, and treatment options...
  6. ncbi Bacteraemia due to tribe Proteeae: a review of 132 cases during a decade (1991-2000)
    Baek Nam Kim
    Division of Infectious Diseases, Keimyung University Dongsan Medical Center, Daegu, Korea
    Scand J Infect Dis 35:98-103. 2003
    ..Providencia bacteraemia was relatively uncommon and it can be associated with infections other than UTI...
  7. pmc The Dienes phenomenon: competition and territoriality in Swarming Proteus mirabilis
    A E Budding
    VU Medical Centre, Department of Medical Microbiology and Infection Prevention, Amsterdam, The Netherlands
    J Bacteriol 191:3892-900. 2009
    ..Dienes line formation has implications for the physiology of swarming and social recognition in bacteria...
  8. ncbi [Proteus bacilli: features and virulence factors]
    Antoni Rozalski
    Zakład Immunobiologii Bakterii, Instytut Mikrobiologii i Immunologii Uniwersytetu Łódzkiego, Poland
    Postepy Hig Med Dosw (Online) 61:204-19. 2007
    ..Below we focus on data concerning the molecular basis of the pathogenicity of Proteus bacilli...
  9. ncbi [Enzymatic resistance to beta lactam antibiotics within the genus Proteus and evaluation of Proteus mirabilis phenotypes and genotypes for resistance to third- and fourth-generation cephalosporins]
    Cynthia Rodriguez
    Cátedra de Análisis Clínicos I, Laboratorio de Bacteriologia, Hospital de Clinicas, Universidad de Buenos Aires, Argentina
    Enferm Infecc Microbiol Clin 23:122-6. 2005
    ..The aim of this study was to evaluate betalactam resistance within the genus Proteus and characterize the betalactamases responsible for this resistance...
  10. ncbi [Proteus penneri]
    Rafael Canton
    Servicio de Microbiologia, Hospital Universitario Ramon y Cajal, Madrid, Espana
    Enferm Infecc Microbiol Clin 24:8-13. 2006
    ..This phenotype resembles the production of an extended spectrum beta-lactamase. Like other Proteus species, P. penneri is resistant to tetracyclines and should be considered resistant to nitrofurantoin...
  11. pmc New plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of Proteus mirabilis
    Minghua Wang
    Institute of Antibiotics, Huashan Hospital, Fudan University, 12 M Wulumuqi Rd, Shanghai 200040, People s Republic of China
    Antimicrob Agents Chemother 53:1892-7. 2009
    ..qnrC could not be detected by PCR, however, in 2,020 strains of Enterobacteriaceae. A new quinolone resistance gene, qnrC, was thus characterized from plasmid pHS10 carried by a clinical isolate of P. mirabilis...
  12. pmc Emerging extended-spectrum beta-lactamases in Proteus mirabilis
    Laura Pagani
    Dipartimento di Scienze Morfologiche, Eidologiche e Cliniche, Sezione di Microbiologia, Universita di Pavia, Italy
    J Clin Microbiol 40:1549-52. 2002
    ..Analysis of clonal diversity of the ESBL producers suggested different spreading patterns for the two ESBL determinants...
  13. ncbi Prevalence of extended-spectrum beta-lactamases in Proteus mirabilis in a Taiwanese university hospital, 1999 to 2005: identification of a novel CTX-M enzyme (CTX-M-66)
    Jiunn Jong Wu
    Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan
    Diagn Microbiol Infect Dis 60:169-75. 2008
    ..mirabilis...
  14. ncbi Nosocomial outbreak by Proteus mirabilis producing extended-spectrum beta-lactamase VEB-1 in a Korean university hospital
    Ja Young Kim
    Department of Clinical Pathology, College of Medicine, The Catholic University of Korea, Kangnam St Mary s Hospital, 505 Banpo Dong, Seocho Ku, Seoul 137 701, Korea
    J Antimicrob Chemother 54:1144-7. 2004
    ..To examine the molecular mechanisms involved in the beta-lactam resistance of multidrug-resistant Proteus mirabilis isolates that showed an unusual synergy between imipenem and ceftazidime in a Korean hospital...
  15. pmc Potential virulence factors of Proteus bacilli
    A Rozalski
    Institute of Microbiology and Immunology, University of Lodz, Poland
    Microbiol Mol Biol Rev 61:65-89. 1997
    ..All these features and factors are described and commented on in detail. The questions important for future investigation of these facultatively pathogenic microorganisms are also discussed...
  16. ncbi Evaluation of a modified double-disc synergy test for detection of extended spectrum beta-lactamases in AMPC beta-lactamase-producing proteus mirabilis
    M K R Khan
    Department of Microbiology, V P Chest Institute, University of Delhi, Delhi 110 007, India
    Indian J Med Microbiol 26:58-61. 2008
    ..The study demonstrated that MDDST is superior to DDST and as sensitive as NCCLS-PDCT. However, MDDST seems to have enhanced potential for the detection of ESBLs in AmpC beta-lactamase-producing P. mirabilis ...
  17. doi Ulcer infection by ESbetaL-producing Proteus mirabilis: a case report
    Vincenzo Savini
    Unità Operativa Complessa di Microbiologia e Virologia Clinica, Dipartimento di Medicina Trasfusionale, Ospedale Civile Spirito Santo, Pescara, Italy
    Int J Low Extrem Wounds 7:99-101. 2008
    ..This article focuses on diffusion and clinical effect of extended-spectrum beta-lactamases-producing Proteus mirabilis on treatment of gram negative lower extremity infections...
  18. ncbi An iron-regulated outer-membrane protein of Proteus mirabilis is a haem receptor that plays an important role in urinary tract infection and in in vivo growth
    Analia Lima
    Laboratorio de Microbiologia, Instituto de Investigaciones Biologicas Clemente Estable, Av Italia 3318, CP 11600, Montevideo, Uruguay
    J Med Microbiol 56:1600-7. 2007
    ..mirabilis 64 kDa iron-regulated OMP is a haem receptor that has an important role for survival and multiplication of these bacteria in the mammalian host and in the development of urinary tract infection...
  19. ncbi Swarming of Proteus mirabilis over ureteral stents: a comparative assessment
    James D Watterson
    Division of Urology, University of Western Ontario, London, Ontario, Canada
    J Endourol 17:523-7. 2003
    ....
  20. ncbi [Bacterial pathogens, resistance patterns and treatment options in community acquired pediatric urinary tract infection]
    L Pape
    Abteilung für pädiatrische Nephrologie und Stoffwechselerkrankungen, Medizinische Hochschule Hannover
    Klin Padiatr 216:83-6. 2004
    ..We intended to evaluate data from northern Germany...
  21. ncbi [Urinary tract infection in institutionalized elderly patients. Incidence of bacterial resistance and risk factors]
    V Faus Felipe
    Servicio de Farmacia, Centro Sociosanitario La Florida, Alicante
    Farm Hosp 27:298-303. 2003
    ....
  22. pmc Molecular epidemiology of Proteus mirabilis infections of the catheterized urinary tract
    N A Sabbuba
    Cardiff School of Biosciences, Cardiff University, Cardiff, United Kingdom
    J Clin Microbiol 41:4961-5. 2003
    ..mirabilis can persist in the urinary tract despite many changes of catheter, periods of noncatheterization, and antibiotic therapy...
  23. doi Increase in beta-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type beta-lactamases
    L M Aragón
    Servei de Microbiologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    J Antimicrob Chemother 61:1029-32. 2008
    ....
  24. ncbi Ascending to a UTI vaccine?
    Sheilagh Clarkson
    Nat Rev Microbiol 2:90. 2004
  25. ncbi Emergence of Proteus mirabilis carrying the bla metallo-beta-lactamase gene
    S Vourli
    Department of Microbiology, National School of Public Health, Athens, Greece
    Clin Microbiol Infect 12:691-4. 2006
    ..This is the first description of the bla(VIM-1) metallo-beta-lactamase gene in P. mirabilis...
  26. ncbi The type III secretion system of Proteus mirabilis HI4320 does not contribute to virulence in the mouse model of ascending urinary tract infection
    Melanie M Pearson
    Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109 0620, USA
    J Med Microbiol 56:1277-83. 2007
    ..The role of the P. mirabilis TTSS, if any, is yet to be determined...
  27. ncbi [Proteus mirabilis community-acquired pneumonia]
    I Villamil Cajoto
    An Med Interna 23:146. 2006
  28. ncbi Triclosan loaded ureteral stents decrease proteus mirabilis 296 infection in a rabbit urinary tract infection model
    Peter A Cadieux
    Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada
    J Urol 175:2331-5. 2006
    ..Using a rabbit model of UTI we examined the effects of triclosan impregnated stent segments on the growth and survival of Proteus mirabilis, a uropathogen commonly associated with device related UTI and encrustation...
  29. ncbi Proteus mirabilis spondylodiscitis complicating a urinary tract infection
    Jeroen P P Smits
    Department of Internal Medicine, Groene Hart Ziekenhuis, Gouda, The Netherlands
    Scand J Infect Dis 38:575-6. 2006
    ..Haematogenous invasion may follow urosepsis. We report on a case of septic spondylodiscitis following urosepsis with Proteus mirabilis, a frequently isolated microorganism in urinary tract infections but rarely in spondylodiscitis...
  30. ncbi Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis
    Ryoichi Saito
    Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan
    J Antimicrob Chemother 58:673-7. 2006
    ..We conducted a study to determine the role played by amino acid mutations in DNA gyrase and topoisomerase IV, and the AcrAB efflux pump in resistance to fluoroquinolones in clinical isolates of Proteus mirabilis...
  31. ncbi There is a low incidence of recurrent bacteriuria in painful bladder syndrome/interstitial cystitis patients followed longitudinally
    Edward Stanford
    Department of Gynecology Urogynecology, Center for Advanced Pelvic Surgery, St Mary s Good Samaritan Hospital, Centralia, IL 62801, USA
    Int Urogynecol J Pelvic Floor Dysfunct 18:551-4. 2007
    ..These data suggest that the symptom flares of IC are not usually associated with recurrent UTI and, therefore, are likely due to a triggering of the other painful mechanisms involved in IC patients who are culture-negative...
  32. ncbi Interspecies spread of CTX-M-32 extended-spectrum beta-lactamase and the role of the insertion sequence IS1 in down-regulating bla CTX-M gene expression
    Ana Fernandez
    Servicio de Microbiología Unidad de Investigación, Complejo Hospitalario, Universitario Juan Canalejo, La Coruna, Spain
    J Antimicrob Chemother 59:841-7. 2007
    ..To characterize the extended-spectrum beta-lactamases (ESBLs) as well as their genetic environment in different isolates of Enterobacteriaceae from a patient with repeated urinary tract infections...
  33. ncbi Rheumatoid arthritis and proteus
    Alan Ebringer
    Clin Med 5:420-1. 2005
  34. ncbi Gudair (OJD) vaccine self-inoculation: a case for early debridement
    Graeme D Richardson
    School of Rural Health, University of New South Wales, Wagga Wagga, NSW
    Med J Aust 183:151-2. 2005
  35. ncbi Acquired AmpC type beta-lactamases: an emerging problem in Italian long-term care and rehabilitation facilities
    Roberta Migliavacca
    Dipartimento di Scienze Morfologiche Eidologiche e Cliniche, Sezione di Microbiologia, Universita di Pavia, Pavia, Italy
    New Microbiol 30:295-8. 2007
    ..These results revealed multifocal spreading of a CMY-16 producing P. mirabilis clone in Northern Italy and emphasize the emergence of similar acquired resistance determinants in the LTCRFs setting...
  36. ncbi Molecular epidemiology of ESbetaL producing P. mirabilis strains from a long-term care and rehabilitation facility in Italy
    Roberta Migliavacca
    Dipartimento di Scienze Morfologiche Eidologiche e Cliniche, Sezione di Microbiologia, Universita di Pavia, Italia
    New Microbiol 30:362-6. 2007
    ..An effective strategy to curtail the spread of ESbetaLs mediated resistance in LTCRFs could be to activate sourveillance programs to monitor routinely the entry of resistant bacteria...
  37. pmc Noninvasive biophotonic imaging for monitoring of catheter-associated urinary tract infections and therapy in mice
    Jagath L Kadurugamuwa
    Xenogen Corporation, 860 Atlantic Avenue, Alameda, California 94501, USA
    Infect Immun 73:3878-87. 2005
    ....
  38. ncbi Molecular diversity of Proteus mirabilis isolates producing extended-spectrum beta-lactamases in a French university hospital
    M Biendo
    Laboratoire de Bactériologie et Hygiène, CHU Nord, France
    Clin Microbiol Infect 11:395-401. 2005
    ..3%) and 12 (26.6%) isolates, respectively. These pulsotypes were considered to represent epidemic strains and spread in various wards of the hospital...
  39. ncbi Crystallization of urine mineral components may depend on the chemical nature of Proteus endotoxin polysaccharides
    Agnieszka Torzewska
    Department of Immunobiology of Bacteria, Institute of Microbiology and Immunology, University of Lodz, Poland
    J Med Microbiol 52:471-7. 2003
    ..This points to the increased importance of endotoxin in urinary tract infections...
  40. ncbi Evaluation of Proteus mirabilis structural fimbrial proteins as antigens against urinary tract infections
    Rafael Pellegrino
    Laboratorio de Microbiologia, Instituto de Investigaciones Biologicas Clemente Estable, Av Italia 3318, P O Box 11600, Montevideo, Uruguay
    FEMS Immunol Med Microbiol 36:103-10. 2003
    ..mirabilis experimental challenges. These results may contribute to the development of vaccines against P. mirabilis, an important cause of complicated UTI...
  41. ncbi Vaccines for Proteus mirabilis in urinary tract infection
    Xin Li
    Department of Microbiology and Immunology, University of Maryland School of Medicine, 655 W Baltimore Street, Room 13 009, Baltimore, MD 21201, USA
    Int J Antimicrob Agents 19:461-5. 2002
    ..mirabilis, is a promising vaccine candidate. Successful vaccination would be expected both to prevent colonization by P. mirabilis and urolithiasis...
  42. ncbi Genotyping of urinary and fecal Proteus mirabilis isolates from individuals with long-term urinary catheters
    S Mathur
    Bristol Urological Institute, Southmead Hospital, Bristol, BS10 5NB, UK
    Eur J Clin Microbiol Infect Dis 24:643-4. 2005
  43. ncbi Detection and mutation of a luxS-encoded autoinducer in Proteus mirabilis
    Rachel Schneider
    Center of Marine Biotechnology, University of Maryland Biotechnology Institute, 701 East Pratt Street, Baltimore, MD 21202, USA
    Microbiology 148:773-82. 2002
    ..While lacking AI-2 activity, a null mutation in luxS, however, did not affect swimming or swarming motility, swarmer cell differentiation, or virulence in a mouse model of ascending urinary tract infection...
  44. pmc Repression of bacterial motility by a novel fimbrial gene product
    X Li
    Department of Microbiology and Immunology, University of Maryland School of Medicine and Veterans Affairs Medical Center, Baltimore, MA 21201, USA
    EMBO J 20:4854-62. 2001
    ..mirabilis strain HI4320 is attenuated in the murine model. Our data also indicate that PapX encoded by a pap (pyelonephritis- associated pilus) operon of uropathogenic Escherichia coli is a functional homolog of MrpJ...
  45. ncbi Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection
    A H Mutnick
    The JONES Group JMI Laboratories, North Liberty, Iowa 52317, USA
    J Chemother 14:253-8. 2002
    ..Imipenem also showed decreased susceptibility of greater than 7% compared to less than 1% for meropenem. Continued surveillance by the MYSTIC Program appears to be a prudent practice to focus effective empiric treatment regimens...
  46. pmc Proteus mirabilis genes that contribute to pathogenesis of urinary tract infection: identification of 25 signature-tagged mutants attenuated at least 100-fold
    Laurel S Burall
    Department of Microbiology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Infect Immun 72:2922-38. 2004
    ....
  47. doi Purple like a glove
    Brandon Eilertson
    Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
    J Hosp Med 3:430. 2008
  48. pmc Urinary tract infection in adolescent boys
    A J Khan
    Meharry Medical College, Brooklyn, New York, USA
    J Natl Med Assoc 88:25-6. 1996
    ..Forty-eight percent showed structural anomalies of the urinary tract. Recurrences were observed only in those having abnormalities of the urinary tract...
  49. ncbi [Amyloidosis associated with chronic granulomatous disease in a patient with a renal transplant and recurrent urinary tract infections]
    R Peces
    Servicio de Nefrologia, Hospital Central de Asturias, Oviedo
    Nefrologia 22:486-91. 2002
    ....
  50. pmc UreR, the transcriptional activator of the Proteus mirabilis urease gene cluster, is required for urease activity and virulence in experimental urinary tract infections
    Jonathan D Dattelbaum
    Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore 21201, USA
    Infect Immun 71:1026-30. 2003
    ..016), and kidneys (P < or = 0.001) 7 days after inoculation. Thus, UreR is required for basal urease activity in the absence of urea, for induction of urease by urea, and for virulence of P. mirabilis in the urinary tract...
  51. ncbi Ascending urinary tract infections in rats induced by Staphylococcus saprophyticus and Proteus mirabilis
    E Hjelm
    Institute of Clinical Bacteriology, University of Uppsala, Sweden
    Acta Pathol Microbiol Immunol Scand B 95:347-50. 1987
    ..The antibody response to the different organisms was the same either the bacteria were instilled separately or in combination...
  52. doi Proteus Takayasu's arteritis with unusual intracranial granulomatosis as initial manifestation
    Yu qiang Chen
    Department of Nephrology and Rheumatology, Sixth People s Hospital Shanghai, Jiao Tong University, 600 Yishan Road, 200233 Shanghai, China
    Rheumatol Int 32:2185-8. 2012
    ....
  53. doi Serotyping of Proteus mirabilis clinical strains based on lipopolysaccharide O-polysaccharide and core oligosaccharide structures
    W Kaca
    Department of Microbiology, Institute of Biology, Jan Kochanowski University, Kielce, Poland
    Biochemistry (Mosc) 76:851-61. 2011
    ..mirabilis UTI stains were identified. The diversity of serological reactions of LPSs is useful for serotyping of P. mirabilis clinical isolates. A possible role of the acidic components of O-antigens in UTI is discussed...
  54. ncbi Complicated coexisting pyogenic and tuberculous otitis media affecting the temporozygomatic, infratemporal, and parotid areas: report of a rare entity
    Tripti Brar
    Department of ENT, Maulana Azad Medical College and Lok Nayak Hospital, New Delhi, India
    Ear Nose Throat J 92:E10-2. 2013
    ..The patient was placed on antituberculosis drug therapy. Although her facial nerve palsy and hearing loss persisted, she otherwise responded well and did not require surgery...
  55. doi Virulence factors in Proteus bacteria from biofilm communities of catheter-associated urinary tract infections
    Veronika Hola
    Faculty of Medicine, Institute for Microbiology, Masaryk University and St Anna Teaching Hospital, Brno, Czech Republic
    FEMS Immunol Med Microbiol 65:343-9. 2012
    ..The virulence factors (twitching motility, swimming motility, swarming over various types of catheters and biofilm formation) were also more intensively expressed...
  56. pmc Cutaneo-pericardial fistula after transapical aortic valve implantation
    Michael Scheid
    Department of Cardiovascular Surgery, University Hospital Schleswig Holstein, Kiel, Germany
    Interact Cardiovasc Thorac Surg 16:558-9. 2013
    ..We report here the case of an 86-year old patient with a cutaneo-pericardial fistula after a transapical TAVI procedure...
  57. doi Antimicrobial activities against biofilm formed by Proteus mirabilis isolates from wound and urinary tract infections
    R Wasfi
    Department of Microbiology, Faculty of Pharmacy, University for Modern Sciences and Arts, Giza, Egypt
    Indian J Med Microbiol 30:76-80. 2012
    ..The aim of the present study was to evaluate the ability of the bacteria, isolated from urinary tract infections (UTIs) and wound infections, to form biofilm and correlate the role of biofilm with their antimicrobial resistance...
  58. doi Synthesis of monodispersed silver nanoparticles using Hibiscus cannabinus leaf extract and its antimicrobial activity
    M R Bindhu
    Department of Physics, Mother Teresa Women s University, Kodaikanal 624 101, Tamil Nadu, India
    Spectrochim Acta A Mol Biomol Spectrosc 101:184-90. 2013
    ..cannabinus leaf extract has been used as reducing agent. The prepared silver nanoparticle shows good antimicrobial activity against Escherichia coli, Proteus mirabilis and Shigella flexneri...
  59. doi [Clinical and molecular characterization of ESBL-producing enterobacteria isolated from bacteremia in a university hospital]
    Patricia García C
    Departamento de Laboratorios Cínicos, Pontificia Universidad Catolica de Chile, Santiago, Chile
    Rev Chilena Infectol 28:563-71. 2011
    ..ESBL-producing enterobacteria that cause bacteremia limit therapeutic options and increase mortality. Objective: To perform a clinical and molecular description of bacteremia caused by ESBL-producing enterobacteria...
  60. doi Effects of Taishan Pinus massoniana pollen polysaccharide on the subunit vaccine of Proteus mirabilis in birds
    Guolin Cui
    College of Animal Science and Technology, Shandong Agricultural University, Taian, Shandong 271018, PR China
    Int J Biol Macromol 56:94-8. 2013
    ..mirabilis; induced stronger humoral, cellular and mucosal immunity as compared with WO and PP; and should be developed as a vaccine adjuvant...
  61. pmc An unusual case of a ureteric hernia into the sciatic foramen causing urinary sepsis: successfully treated laparoscopically
    C Witney-Smith
    Department of Urology, Royal Free Hospital, London, UK
    Ann R Coll Surg Engl 89:W10-2. 2007
    ..The presentation was that of a 59-year-old woman with urinary tract sepsis associated with an acute deterioration of renal function. The hernia was successfully repaired laparoscopically...
  62. ncbi Rheumatoid arthritis is caused by Proteus: the molecular mimicry theory and Karl Popper
    Alan Ebringer
    Analytical Sciences Group, King s College, London, England
    Front Biosci (Elite Ed) 1:577-86. 2009
    ..Anti-Proteus therapy should be assessed in the management of this disease separately or in conjunction with existing modalities of therapy...
  63. pmc Oxygen-limiting conditions enrich for fimbriate cells of uropathogenic Proteus mirabilis and Escherichia coli
    M Chelsea Lane
    Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, 48109 0620, USA
    J Bacteriol 191:1382-92. 2009
    ..These findings provide evidence to support a mechanism for persistence of fimbriate bacteria under oxygen limitation, which is relevant to disease progression within the oxygen-restricted urinary tract...
  64. doi Henoch-Schönlein purpura associated with Proteus mirabilis urinary tract infection
    Petros I Rafailidis
    J Am Acad Dermatol 58:S98-9. 2008
  65. pmc Antimicrobial photodynamic therapy combined with conventional endodontic treatment to eliminate root canal biofilm infection
    Aguinaldo S Garcez
    Center for Lasers and Applications, IPEN CNEN SP, Sao Paulo, SP, Brazil
    Lasers Surg Med 39:59-66. 2007
    ..To compare the effectiveness of antimicrobial photodynamic therapy (PDT), standard endodontic treatment and the combined treatment to eliminate bacterial biofilms present in infected root canals...
  66. doi Crossed fused renal ectopia with calculi
    Bimal C Ghosh
    SUNY Downstate New York Harbor Healthcare System, Brooklyn, NY, USA
    J Am Coll Surg 206:753. 2008
  67. ncbi Effects of the administration of cholera toxin as a mucosal adjuvant on the immune and protective response induced by Proteus mirabilis MrpA fimbrial protein in the urinary tract
    Paola Scavone
    Department of Microbiology, Institute of Biological Investigations Clemente Estable, UDELAR, Montevideo, Uruguay
    Microbiol Immunol 53:233-40. 2009
    ..Further studies are necessary to understand immune modulation in the urinary tract...
  68. doi A novel autotransporter of uropathogenic Proteus mirabilis is both a cytotoxin and an agglutinin
    Praveen Alamuri
    Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109 0620, USA
    Mol Microbiol 68:997-1017. 2008
    ..mirabilis infection...
  69. ncbi Soft tissue infections with Arcanobacterium haemolyticum: report of three cases
    A Malini
    Department of Microbiology, Sri Devaraj Urs Medical College, Tamaka, Kolar, Karnataka 563 101, India
    Indian J Med Microbiol 26:192-5. 2008
    ..Erythromycin alone or combined therapy of penicillin with erythromycin or penicillin with ciprofloxacin was effective in treating these infections...
  70. ncbi [Lower urinary tract infections: bacterial epidemiology and recommendations]
    Eugenie Bergogne-Berezin
    Antibiotiques, Thérapeutique Antiinfectieuses, Elsevier Masson, Paris
    Prog Urol 18:F11-4. 2008
    ..The control of lower urinary tract infections remains relatively easy provided that a good therapeutic choice is based on well documented bacteriologic data (infecting species susceptible to the available antibiotics)...
  71. pmc Purple urine bag syndrome
    Che Kim Tan
    Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan
    CMAJ 179:491. 2008
  72. ncbi Surveillance of antimicrobial susceptibility of urinary pathogens in a tertiary care hospital
    Subhash C Arya
    Singapore Med J 48:270-1; author reply 271. 2007
  73. doi The high-affinity phosphate transporter Pst is a virulence factor for Proteus mirabilis during complicated urinary tract infection
    Sandra M Jacobsen
    Department of Microbiology and Immunology, School of Medicine, University of Maryland Baltimore, Baltimore, MD, USA
    FEMS Immunol Med Microbiol 52:180-93. 2008
    ..mirabilis that is not required for in vitro growth. Thus, the Pst transporter has satisfied molecular Koch's postulates as a virulence factor in the pathogenesis of urinary tract infection caused by P. mirabilis...
  74. ncbi Protean infectious types and frequent association with neurosurgical procedures in adult Serratia marcescens CNS infections: report of two cases and review of the literature
    C R Huang
    Department of Neurology, Chang Gung Memorial Hospital-Kaohsiung, 123, Ta Pei Road, Niao Sung Hsiang, Hsien, Kaohsiung, Taiwan, ROC
    Clin Neurol Neurosurg 103:171-4. 2001
    ..Antibiotic therapy with or without neurosurgical intervention was the management strategy in 14/15 cases. The therapeutic results showed a high mortality rate...
  75. ncbi [Epidemiology of ESBL-positive Enterobacteriaceae in Mantova hospital (Italy)]
    Gianni Gattuso
    Unita Operativa Malattie Infettive, Azienda Ospedaliera Carlo Poma, Mantova, Italy
    Infez Med 17:164-8. 2009
    ..The study enabled the change in the relative epidemiological data to be detected, and showed that such bacteria can be found almost throughout the hospital...
  76. doi Structural and serological studies of the O-polysaccharide of strains from a newly created Proteus O78 serogroup prevalent in Polish patients
    Dominika Drzewiecka
    Department of General Microbiology, University of Lodz, Lodz, Poland
    FEMS Immunol Med Microbiol 58:269-76. 2010
    ..Based on these data, we propose to classify the strains studied as a new serogroup in the genus Proteus named O78...
  77. pmc RmtC 16S rRNA methyltransferase in Australia
    Zhiyong Zong
    Antimicrob Agents Chemother 52:794-5. 2008
  78. doi Prevalence of Proteus mirabilis in skin abscesses of the axilla
    Rakesh D Mistry
    Division of Emergency Medicine, Department of Pediatrics, Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Pediatr 156:850-1. 2010
    ..In this report, we describe a high prevalence of Proteus mirabilis, a Gram-negative bacillus, in skin abscesses of the axilla, which has potential implications for selection of antimicrobial therapy...
  79. ncbi Microbial keratitis in a case of lamellar ichthyosis
    Sunita Chaurasia
    L V Prasad Eye Institute, Hyderabad, Andhra Pradesh, India
    Int Ophthalmol 28:367-8. 2008
    ..He was treated with topical ciprofloxacin and fortified cefazolin eyedrops. Microbial keratitis in patients with lamellar ichthyosis has a poor prognosis...
  80. doi Asymptomatic bacteriuria during pregnancy
    Eyal Sheiner
    Faculty of Health Sciences, The Department of Obstetrics and Gynecology, Soroka University Medical Center, Be er Sheva, Israel
    J Matern Fetal Neonatal Med 22:423-7. 2009
    ..Our study was also designed to characterize common bacteria and risk factors associated with asymptomatic bacteriuria during pregnancy...
  81. doi Selective strategy for urethral catheterization in febrile young girls to confirm urinary tract infection diagnosis
    C Runel-Belliard
    Department of Emergency Medicine, Armand Trousseau Hospital, AP HP, University Paris VI, Paris, France
    Nephron Clin Pract 116:c235-40. 2010
    ..We aimed to derive a clinical decision rule to identify non-toilet-trained febrile girls at high risk for UTIs to restrict urethral catheterizations (UCs) to this high-risk group of patients...
  82. pmc Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Proteus mirabilis bacteremia
    Kyung mok Sohn
    Division of Infectious Diseases, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Korean J Intern Med 26:89-93. 2011
    ..We evaluated the clinical features of ciprofloxacin-resistant Proteus mirabilis bacteremia and risk factors for ciprofloxacin resistance...
  83. doi Potential use of 68Ga-apo-transferrin as a PET imaging agent for detecting Staphylococcus aureus infection
    Vijay Kumar
    Department of Nuclear Medicine and PET, Westmead Hospital, Westmead, Syndney, Australia
    Nucl Med Biol 38:393-8. 2011
    ..The present project explored whether (68)Ga-apo-transferrin ((68)Ga-TF), when prepared in vitro, is a useful agent for positron emission tomography (PET) imaging of bacterial infection...
  84. ncbi [Proteus mirabilis isolated from urine, resistance to antibiotics and biofilm formation]
    Lenka Cernohorská
    Microbiological Department, Masaryk University, St Anne s University Hospital Brno, Czech Republic
    Klin Mikrobiol Infekc Lek 17:81-5. 2011
    ..In the rather rare urinary pathogen Proteus mirabilis resistance to antibiotics and ability to form biofilm were studied...
  85. ncbi Preventing catheter-related urinary tract infection: focus on Proteus mirabilis
    Linda Nazarko
    Ealing NHS Trust
    Br J Community Nurs 16:528, 530-3. 2011
    ..However, it is important that staff are able to recognise the features of a Proteus infection. Proteus infections, if unrecognised, can become established and cause major health problems...
  86. pmc Characterization of a new extended-spectrum beta-lactamase (TEM-87) isolated in Proteus mirabilis during an Italian survey
    Mariagrazia Perilli
    Dipartimento di Scienze e Tecnologie Biomediche, Universita di L Aquila, L Aquila, Italy
    Antimicrob Agents Chemother 46:925-8. 2002
    ..Kinetic analysis of TEM-87 revealed extended-spectrum activity against oxyimino cephalosporins (preferentially ceftazidime) and aztreonam. Expression of blaTEM-87 in Escherichia coli decreased the host susceptibility to these drugs...
  87. pmc Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis
    Xin Li
    Department of Microbiology and Immunology, University of Michigan Medical School, 5641 Medical Science Bldg II, 1150 West Medical Center Drive, Ann Arbor, MI 48109, USA
    Infect Immun 72:7306-10. 2004
    ..This chimera, when administered intranasally without additional adjuvant, is sufficient to induce protective immunity in mice...
  88. ncbi Clinical relevance of Proteus mirabilis in hospital patients: a two year survey
    C De Champs
    Laboratoire de Bacteriologie, Faculte de Medecine, 28, Place Henri Dunant, 63001 Clermont Ferrand cedex, France
    J Antimicrob Chemother 45:537-9. 2000
    ..ESBL-producing isolates were observed in long-stay and intensive care and IRB-producing isolates in paediatric units. Of the 95 patients whose charts were examined, 69 had a confirmed infection, which in 42 cases was nosocomial...
  89. ncbi Plasmid-mediated multiple antibiotic resistance in Proteus mirabilis isolated from patients with urinary tract infection
    Asad U Khan
    Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, India
    Med Sci Monit 10:CR598-602. 2004
    ..We initiated this study to learn the drug resistance pattern and its location (genomic or plasmid-borne) among the strains of Proteus mirabilis, one of the most common causative agents of urinary tract infection (UTI)...
  90. ncbi Mucosal vaccination of mice with recombinant Proteus mirabilis structural fimbrial proteins
    Paola Scavone
    Laboratorio de Microbiologia, Instituto de Investigaciones Biologicas Clemente Estable, Avda Italia 3318, Montevideo CP11600, Uruguay
    Microbes Infect 6:853-60. 2004
    ..mirabilis UTI. Further studies are being carried out to characterise the immune and inflammatory response induced by P. mirabilis recombinant fimbrial subunits...
  91. ncbi Characterization of CMY-type beta-lactamases in clinical strains of Proteus mirabilis and Klebsiella pneumoniae isolated in four hospitals in the Paris area
    Dominique Decré
    Service de Bacteriologie, Hopital Saint Antoine, UFR Saint Antoine, 184 rue du Faubourg Saint Antoine, 75012 Paris, France
    J Antimicrob Chemother 50:681-8. 2002
    ..pneumoniae strains was recovered from a French patient. PFGE analysis and rep-PCR fingerprinting showed that the two P. mirabilis isolates from Greek patients were closely related...
  92. ncbi Images in clinical medicine. Unusual cystitis
    Keyvan Ravakhah
    Huron Hospital, Cleveland Clinic Health System, Cleveland, OH 44112, USA
    N Engl J Med 350:2280. 2004
  93. pmc Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis
    Xin Li
    Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Infect Immun 72:66-75. 2004
    ..Intranasal immunization of CBA mice with MBP-MrpH (residues 23 to 157) conferred effective protection against urinary tract infection by P. mirabilis (P < 0.002)...
  94. ncbi Comparative efficacy of gemifloxacin in experimental models of pyelonephritis and wound infection
    V Berry
    SmithKline Beecham Pharmaceuticals, Collegeville, PA 19426 0989, USA
    J Antimicrob Chemother 45:87-93. 2000
    ..pyogenes or S. aureus infections. These data demonstrate the potential benefit of gemifloxacin in the treatment of Gram-negative urinary tract infection and Gram-positive skin and soft tissue infection...
  95. ncbi Staghorn calculus in renal allograft presenting as acute renal failure
    Charuhas V Thakar
    Department of Nephrology and Hypertension, The Cleveland Clinic Foundation, Desk A 51, 9500 Euclid Avenue, Cleveland OH 44195, USA
    Urol Res 31:414-6. 2003
    ..Urolithiasis is a rare complication in renal transplant recipients. We report a case of a staghorn calculus occurring in renal allograft, presenting as anuric renal failure with Gram-negative sepsis...
  96. ncbi Virulence of a Proteus mirabilis ATF isogenic mutant is not impaired in a mouse model of ascending urinary tract infection
    P Zunino
    Division Microbiologia, Instituto de Investigaciones Biologicas Clemente Estable, Montevideo, Uruguay
    FEMS Immunol Med Microbiol 29:137-43. 2000
    ..mirabilis isolates showed a reactive AtfA band after Western blot analysis using a polyclonal rabbit AtfA antiserum. These data together suggest that ATF does not play a role in P. mirabilis urinary tract infection...
  97. pmc Identification of Proteus mirabilis mutants with increased sensitivity to antimicrobial peptides
    A J McCoy
    Department of Microbiology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229-3900, USA
    Antimicrob Agents Chemother 45:2030-7. 2001
    ..These data further support the role of LPS modifications as an elaborate mechanism in the resistance of certain bacterial species to APs and suggest that LPS surface charge alterations may play a role in P. mirabilis swarming motility...
  98. ncbi [Pyomyositis]
    Tine Weis Jacobsen
    H S Hvidovre Hospital, ortopaedkirurgisk afdeling, Radiologisk Afdeling, Infektionsmedicinsk Afdeling
    Ugeskr Laeger 165:1569. 2003
    ..It is a rare condition which cannot easily be diagnosed. A fatal case of pyomyositis in a 78-year-old man is presented. The clinical signs and diagnostics of pyomyositis are discussed...
  99. ncbi Rheumatoid arthritis: proposal for the use of anti-microbial therapy in early cases
    Alan Ebringer
    Division of Life Sciences, Infection and Immunity Group, King s College London, UK
    Scand J Rheumatol 32:2-11. 2003
    ..Such measures could be used as possible additional adjuncts to the standard therapy with NSAIDs and DMARDs...
  100. ncbi The incidence and beta-lactam resistance of Proteus vulgaris in hospital infections: the last decade
    A Gomez-Alferez
    Servicio de Microbiologia, Hospital Ramon y Cajal, Instituto Nacional de la Salud, Madrid, Spain
    J Chemother 3:283-8. 1991
    ..Cefotaxime-resistance was detected in 2% of the isolates which appeared in the period 1987-1990...
  101. ncbi A case of purple urine bag syndrome (PUBS)
    Georg Roggla
    Abteilung fur Innere Medizin, AKH Neunkirchen, Peischingerstrasse 19, A 2620 Neunkirchen, Austria
    Wien Klin Wochenschr 114:306. 2002

Research Grants36

  1. Molecular Pathogenesis of E. Coli UTI
    HARRY MOBLEY; Fiscal Year: 2006
    ..coli in the urinary tract and to develop preventative strategies based on our understanding of the mechanism of this organism's pathogenesis. ..
  2. Reciprocal Control of Motility and Adherence in UTI
    HARRY MOBLEY; Fiscal Year: 2007
    ..Clearly the ability to colonize mucosal surfaces in the respiratory, intestinal, and genital tracts also require the orchestrated synthesis of fimbriae for adherence and flagella for motility. ..
  3. UREASE AND GENE EXPRESSION OF HELICOBACTER PYLORI
    HARRY MOBLEY; Fiscal Year: 2007
    ..The long-term goals of the study are to understand the mechanism by which H. pylori can colonize the gastric mucosa and to identity more effective targets for therapeutic intervention. ..
  4. Molecular Pathogenesis of E. Coli UTI
    HARRY MOBLEY; Fiscal Year: 2009
    ..Here, we present a plan to systematically identify surface-exposed proteins that are synthesized in vivo and are specific to uropathogenic strains of E. coli for use in a vaccine to prevent urinary tract infection. ..
  5. Development of a Urea Biosensor Using the UreR Protein
    HARRY MOBLEY; Fiscal Year: 2004
    ..abstract_text> ..
  6. UREASE AND GENE EXPRESSION IN CAMPYLOBACTER PYLORI
    HARRY MOBLEY; Fiscal Year: 1991
    ..pylori; 2) isolate and express urease gene sequences of C. pylori; 3) develop a system for genetic manipulation of C. pylori; and 4) construct a urease-deficient mutant of C. pylori by homologous recombination...
  7. MOLECULAR PATHOGENESIS OF E COLI UTI
    HARRY MOBLEY; Fiscal Year: 2001
    ..coli CFT073; and 4) To determine the position (On-Off) of the fim invertible element that controls transcription of Type 1 fimbria genes during acute urinary tract infection caused by E. coli. ..
  8. UREASE AND GENE EXPRESSION OF HELICOBACTER PYLORI
    HARRY MOBLEY; Fiscal Year: 2003
    ..3) To determine the gene products that mediate transport of nickel ions across the inner and outer membranes of H. pylori. ..